Who is sponsoring NCT03949946?

NCT03949946 is sponsored by University of Aberdeen.

What drugs are being tested in NCT03949946?

Interventions in NCT03949946: Magnetic resonance imaging (MRI).

What condition does NCT03949946 study?

NCT03949946 studies Breast Cancer.

Is NCT03949946 still recruiting?

NCT03949946 is currently status unknown. Last updated 18 November 2020.

Last reviewed 2020-11-18 · How we verify

NCT03949946

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Is Lipid Mapping an Effective Early Detection Tool for Breast Cancer in High-risk Populations?

Status unknown Last updated 18 November 2020

What this trial tests

trial testing Magnetic resonance imaging (MRI) in Breast Cancer in 40 participants. Status unknown.

Timeline

20 June 2019

Primary endpoint
30 November 2021

31 December 2021

Quick facts

Lead sponsor	University of Aberdeen
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	40
Start date	20 June 2019
Primary completion	30 November 2021
Estimated completion	31 December 2021
Sites	1 location across United Kingdom

Drugs / interventions tested

Magnetic resonance imaging (MRI)

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

University of Aberdeen

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate if lipid composition mapping using magnetic resonance imaging could improve early and accurate cancer detection in genetic mutation carriers at high risk of breast cancer. It is hypothesised that there is a significant difference in the extent of spatial variation in lipid composition in breast from MRI between genetic mutation carriers and patients with breast cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Reprogramming of Lipid Metabolism Mediates Crosstalk, Remodeling, and Intervention of Microenvironment Components in Breast Cancer.
Wang J, Zhang W, Liu C, Wang L, et al · · 2024 · cited 30× · PMID 38481820 · DOI 10.7150/ijbs.92125
Contribution of n-3 Long-Chain Polyunsaturated Fatty Acids to the Prevention of Breast Cancer Risk Factors.
Fodil M, Blanckaert V, Ulmann L, Mimouni V, et al · · 2022 · cited 13× · PMID 35805595 · DOI 10.3390/ijerph19137936

Verify or expand the search:

Other trials of Magnetic resonance imaging (MRI)

Trials testing the same drug.

NCT07447076 — Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT) · Phase 2 · not yet recruiting
NCT07506239 — Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma · NA · recruiting
NCT07121972 — Mirai-MRI: Validation of AI Models for Breast Cancer Risk · NA · recruiting
NCT06246942 — Physiology of Human Brain Connectivity · NA · recruiting
NCT05868928 — Imaging Features for the Risks for Recurrence After Stereotactic Radiosurgery in Brain Metastasis · recruiting

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other University of Aberdeen trials

Trials by the same sponsor.

NCT07070765 — Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity · NA · not yet recruiting
NCT07065383 — Rebalancing the Fat Content of the Heart and Muscles · NA · recruiting
NCT06735573 — Protein, Sarcopenic Obesity, and COPD · not yet recruiting
NCT06714656 — Drivers and Barriers for Adopting Healthy and Sustainable Food Swaps in Young · NA · recruiting
NCT06721312 — Continuous Heart Rate Variability Monitoring in Doctors; Understanding Patterns of Stress and Recovery and Their Relatio · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03949946 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Aberdeen
Last refreshed: 18 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03949946.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing